The use and pharmaceutical composition of Isofol Medical AB’s [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy, has received a patent from the U.S. Patent and Trademark Office.

Modufolin® is a folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment.

Isofol provided evidence demonstrating the success of Modufolin® over folic acid in reducing pemetrexed toxicity. “I am very pleased that the superiority of Modufolin® has been accepted by the United States Patent and Trademark Office and that this patent has been allowed. It will provide Modufolin® with long-term market exclusivity in this application,” said Anders Rabbe, CEO of Isofol Medical.

Modufolin® is currently being evaluated in two Phase I/II studies, in colorectal cancer and in osteosarcoma.

Source: Isofol Medical AB